Novel marker vaccines against classical swine fever

Vaccine

Volumn 25, Issue 30 SPEC. ISS., 2007, Pages 5665-5670

  Beer, Martin ^a   Reimann, Ilona ^a   Hoffmann, Bernd ^a   Depner, Klaus ^a  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

Author keywords

Classical swine fever virus (CSFV); Differentiating infected from vaccinated animals (DIVA); Marker diagnostics; Marker vaccines

Indexed keywords

ANTIBODY; DNA VACCINE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; LIVE VACCINE; MARKER VACCINE; PROTEIN SUBUNIT; PSEUDORABIES VACCINE; RECOMBINANT PARAPOX VIRUS GLYCOPROTEIN E2 VACCINE; RECOMBINANT PORCINE ADENOVIRUS GLYCOPROTEIN E2 VACCINE; RECOMBINANT PROTEIN; RECOMBINANT PSEUDORABIES VIRUS GLYCOPROTEIN E2 VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; DRUG EFFICACY; DRUG SAFETY; GENE CONSTRUCT; GENETIC ENGINEERING; IMMUNOGENICITY; INSECT CELL; NONHUMAN; PESTIVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; SWINE DISEASE; VACCINATION; VIRUS GENOME;

EID: 34447106750     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.036     Document Type: Article

References (50)

1. Hulst M.M., Westra D.F., Wensvoort G., and Moormann R.J. Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera. J Virol 67 9 (1993) 5435-5442
2. Luetticken D., Drexler C., Visser N., and Kaden V. The relevance of CSF marker vaccines for field use. Proceedings of OIE symposium on classical swine fever (Hog Cholera). Birmingham, U.K., July 9-10 (1998)
3. van Oirschot J.T. Diva vaccines that reduce virus transmission. J Biotechnol 73 2-3 (1999) 195-205
4. van Rijn P.A., Bossers A., Wensfort G., and Moormann R.J. Classical swine fewer virus (CSFV) envelope glycoprotein E2 containing one structural antigenic unit protects pigs from lethal CSFV challenge. J Gen Virol 77 11 (1996) 2737-2745
5. Bouma A., de Smit A.J., de Kluijver E.P., Terpstra C., and Moormann R.J. Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus. Vet Microbiol 66 2 (1999) 101-114
6. Uttenthal A., Le Potier M.F., Romero L., DeMia G.M., and Floegel-Niesmann G. Classical swine fever (CSF) marker vaccine Trial I. Challenge study in weaner pigs. Vet Microbiol 83 2 (2001) 85-106
7. Depner K.R., Bouma A., Koenen F., Klinkenberg D., Lange E., de Smit H., et al. Classical swine fever (CSF) marker vaccine Trial II: Challenge study in pregnant sows. Vet Microbiol 83 2 (2001) 107-120
8. Meyers G., Tautz N., Becher P., Thiel H.J., and Kümmerer B.M. Recovery of cytopathogenic and noncytopathogenic bovine viral diarrhea viruses from cDNA constructs. J Virol 70 3 (1996) 8606-8613
9. Moormann R.J., van Gennip H.G., Miedema G.K., Hulst M.M., and van Rijn P.A. Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. J Virol 70 2 (1996) 763-770
10. Ruggli N., Tratschin J.D., Mittelholzer C., and Hofmann MA. Nucleotide sequence of classical swine fever virus strain Alfort/187 and transcription of infectious RNA from stably cloned full-length cDNA. J Virol 70 6 (1996) 3478-3487
11. Vassilev B.V., Collet M.S., and Donis R.O. Authentic and chimeric full-length genomic cDNA clones of bovine viral diarrhea virus that yield infectious transcrips. J Virol 71 1 (1997) 471-478
12. van Rijn P.A., van Gennip H.G., and Moormann R.J. An experimental marker vaccine and accompanying serological diagnostic test both based on envelope glycoprotein E2 of classical swine fever virus (CSFV). Vaccine 17 5 (1999) 433-440
13. de Smit A.J., van Gennip H.G., Miedema G.K., van Rijn P.A., Terpstra C., and Moormann R.J. Recombinant classical swine fever (CSF) viruses derived from the Chinese vaccine strain (C-strain) of CSF virus retain their avirulent and immunogenic characteristics. Vaccine 18 22 (2000) 2351-2358
14. van Gennip H.G., van Rijn P.A., Widjojoatmodjo M.N., de Smit A.J., and Moormann R.J. Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response. Vaccine 19 4-5 (2000) 447-459
15. Widjojoatmodjo M.N., van Gennip H.G., Bouma A., van Rijn P.A., and Moormann R.J. Classical swine fever virus E(rns) deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines. J Virol 74 7 (2000) 2973-2980
16. de Smit A.J., Bouma A., de Kluijver E.P., Terpstra C., and Moormann R.J. Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination. Vet Microbiol 78 4 (2001) 307-317
17. Floegel-Niesmann G. Classical swine fever (CSF) marker vaccine. Trial III. Evaluation of discriminatory ELISAs. Vet Microbiol 83 2 (2001) 121-136
18. Dong X.N., Wei K., Liu Z.Q., and Chen Y.H. Candidate peptide vaccine induced protection against classical swine fever virus. Vaccine 21 3-4 (2002) 167-173
19. Dong X.N., Chen Y., Wu Y., and Chen Y.H. Candidate multi-peptide-vaccine against classical swine fever virus induced potent immunity with serological marker. Vaccine 23 28 (2005) 3630-3633
20. Dong X.N., Qi Y., Ying J., Chen X., and Chen Y.H. Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2. Vaccine 24 4 (2006) 426-434
21. Dong X.N., and Chen Y.H. Candidate peptide-vaccines induced immunity against CSFV and identified sequential neutralizing determinants in antigenic domain A of glycoprotein E2. Vaccine 24 11 (2006) 1906-1913
22. Dong X.N., and Chen Y.H. Spying the neutralizing epitopes on E2 N-terminal by candidate epitope-vaccines against classical swine fever virus. Vaccine 24 19 (2006) 4029-4034
23. Liu S., Tu C., Wang C., Yu X., Wu J., Guo S., et al. The protective immune response induced by B cell epitope of classical swine fever virus glycoprotein E2. J Virol Methods 134 (2006) 125-129
24. Andrew M.E., Morrissy C.J., Lenghaus C., Oke P.G., Sproat K.W., Hodgson A.L., et al. Coupar BE Protection of pigs against classical swine fever with DNA-delivered gp55. Vaccine 18 18 (2000) 1932-1938
25. Harpin S., Talbot B., Mbikay M., and Elazhary Y. Immune response to vaccination with DNA encoding the bovine viral diarrhoea virus major glycoprotein gp53 (E2). FEMS Microbiol Lett 146 2 (1997) 229-234
26. Yu X., Tu C., Li H., Hu R., Chen C., Li Z., et al. DNA-mediated protection against classical swine fever virus. Vaccine 19 11-12 (2001) 1520-1525
27. Nobiron I., Thompson I., Brownlie J., and Collins M.E. DNA vaccination against bovine viral diarrhoea virus induces humoral and cellular responses in cattle with evidence for protection against viral challenge. Vaccine 21 17-18 (2003) 2082-2092
28. Ganges L., Barrera M., Nunez J.I., Blanco I., Frias M.T., Rodriguez F., et al. A DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge. Vaccine 23 28 (2005) 3741-3752
29. Liang R., van den Hurk J.V., Zheng C., Yu H., Pontarollo R.A., Babiuk L.A., et al. Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine 23 45 (2005) 5252-5262
30. Wienhold D., Armengol E., Marquardt A., Marquardt C., Voigt H., Buttner M., et al. Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination. Vet Res 36 4 (2005) 571-587
31. Andrew M., Morris K., Coupar B., Sproat K., Oke P., Bruce M., et al. Porcine interleukin-3 enhances DNA vaccination against classical swine fever. Vaccine 24 16 (2006) 3241-3247
32. König M., Lengsfeld T., Pauly T., Stark R., and Thiel H.J. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. J Virol 69 10 (1995) 6479-6486
33. van Zijl M., Wensvoort G., de Kluyver E., Hulst M., van der Gulden H., Gielkens A., et al. Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera. J Virol 65 5 (1991) 2761-2765
34. Hooft van Iddekinge B.J., de Wind N., Wensvoort G., Kimman T.G., Gielkens A.L., and Moormann R.J. Comparison of the protective efficacy of recombinant pseudorabies viruses against pseudorabies and classical swine fever in pigs; influence of different promoters on gene expression and on protection. Vaccine 14 1 (1996) 6-12
35. Mulder W.A., Priem J., Glazenburg K.L., Wagenaar F., Gruys E., Gielkens A.L., et al. Virulence and pathogenesis of non-virulent and virulent strains of pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus. J Gen Virol 75 1 (1994) 117-124
36. Peeters B., Bienkowska-Szewczyk K., Hulst M., Gielkens A., and Kimman T. Biologically safe, non-transmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever. J Gen Virol 78 12 (1997) 3311-3315
37. Hammond J.M., McCoy R.J., Jansen E.S., Morrissy C.J., Hodgson A.L., and Johnson M.A. Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine 18 11-12 (2000) 1040-1050
38. Hammond J.M., Jansen E.S., Morrissy C.J., Williamson M.M., Hodgson A.L., and Johnson M.A. Oral and sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 gene. Arch Virol 146 9 (2001) 1787-1793
39. Hammond J.M., Jansen E.S., Morrissy C.J., Hodgson A.L., and Johnson M.A. Protection of pigs against 'in contact' challenge with classical swine fever following oral or subcutaneous vaccination with a recombinant porcine adenovirus. Virus Res 97 2 (2003) 151-157
40. Hammond J.M., and Johnson M.A. Porcine adenovirus as a delivery system for swine vaccines and immunotherapeutics. Vet J 169 1 (2005) 17-27
41. Hahn J., Park S.H., Song J.Y., An S.H., and Ahn B.Y. Construction of recombinant swinepox viruses and expression of the classical swine fever virus E2 protein. J Virol Methods 93 1-2 (2001) 49-56
42. Voigt H. Rekombinante Parapockenvakzine gegen klassische Schweinepest: Vergleichende Charakterisierung der Immunreaktionen im Schwein. Inaugural-Dissertation LMU München; 2005.
43. Reimann I., Depner K., Trapp S., and Beer M. An avirulent chimeric pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus. Virology 322 1 (2004) 143-157
44. de Smit A.J., Bouma A., de Kluijver E.P., Terpstra C., and Moormann R.J. Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination. Vet Microbiol 78 4 (2001) 307-317
45. van Gennip H.G., Bouma A., van Rijn P.A., Widjojoatmodjo M.N., and Moormann R.J. Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV. Vaccine 20 11-12 (2002) 1544-1556
46. Maurer R., Stettler P., Ruggli N., Hofmann M.A., and Tratschin J.D. Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV. Vaccine 23 (2005) 3318-3328
47. Frey C.F., Bauhofer O., Ruggli N., Summerfield A., Hofmann M.A., and Tradschin J.D. Classical swine fewer virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application. Vet Res 37 5 (2006) 655-670
48. Hoffmann B., Depner K., Schirrmeier H., and Beer M. A universal heterologous internal control system for duplex real-time RT-PCR assays used in a detection system for pestiviruses. J Virol Methods 136 1-2 (2006) 200-209
49. Hoffmann B., Beer M., Schelp C., Schirrmeier H., and Depner K. Validation of a real-time RT-PCR assay for sensitive and specific detection of classical swine fever. J Virol Methods 130 1-2 (2005) 36-44
50. Depner K, Hoffmann B, Beer M. Does real-time RT-PCR for CSF mark the beginning of a paradigm shift in the control of CSF? In: Vennier P, Espeseth D, editors, New diagnostic technology: applications in animal health and biologics controls, vol. 126. Dev Biol (Basel). Basel, Karger; 2006. p. 115-6.